Evidence map›Paper›PMID 36277396›Full record

ReviewFrontiers in bioengineering and biotechnology2022

Polymeric nanoparticles-Promising carriers for cancer therapy.

Xiao Xiao, Fei Teng, Changkuo Shi, Junyu Chen, Shuqing Wu, Bao Wang, Xiang Meng, Aniekan Essiet Imeh, Wenliang Li

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 146 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Potential of Nanoparticle-Based Phototherapies for Future Treatment of Uveal Melanoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Antibody-conjugated polymer nanoparticles for brain cancer.Drug delivery and translational research · 2025
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xiao XiaoSchool of Pharmacy, Jilin Medical University, Jilin, China.
Fei TengSchool of Pharmacy, Jilin Medical University, Jilin, China.
Changkuo ShiSchool of Pharmacy, Jilin Medical University, Jilin, China.
Junyu ChenSchool of Pharmacy, Jilin Medical University, Jilin, China.
Shuqing WuSchool of Pharmacy, Jilin Medical University, Jilin, China.
Bao WangSchool of Chemistry and Environmental Engineering, Changchun University of Science and Technology, Changchun, China.
Xiang MengSchool of Pharmacy, Jilin Medical University, Jilin, China.
Aniekan Essiet ImehSchool of Clinical Medicine, Jilin Medical University, Jilin, China.
Wenliang LiSchool of Pharmacy, Jilin Medical University, Jilin, China.
Jilin Medical University · CNChangchun University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polymeric nanoparticles (NPs) play an important role in controlled cancer drug delivery. Anticancer drugs can be conjugated or encapsulated by polymeric nanocarriers, which are known as polymeric nanomedicine. Polymeric nanomedicine has shown its potential in providing sustained release of drugs with reduced cytotoxicity and modified tumor retention, but until now, few delivery systems loading drugs have been able to meet clinical demands, so more efforts are needed. This research reviews the current state of the cancer drug-loading system by exhibiting a series of published articles that highlight the novelty and functions from a variety of different architectures including micelles, liposomes, dendrimers, polymersomes, hydrogels, and metal-organic frameworks. These may contribute to the development of useful polymeric NPs to achieve different therapeutic purposes.

Indexed as

cancer drug deliverynanocarrierpH-sensitivepolymeric nanoparticlethermo-sensitive

Identifiers

PMID36277396
PMCPMC9585261
OpenAlexW4303044684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.